| |
Neither APR elevated
|
APR levels discordant
|
Both APR elevated
|
P value
|
|---|
| |
n = 1,012
|
n = 487
|
n = 324
| |
|---|
|
Age (years)
|
60.92 ± 13.49
|
63.24 ± 13.51
|
64.26 ± 12.79
|
<0.0001
|
|
Duration of RA (years)
|
8.62 ± 9.37
|
9.55 ± 10.46
|
7.47 ± 8.38
|
0.0074
|
|
One-year follow-up duration (days)
|
363.43 ± 29.79
|
364.78 ± 31.48
|
365.43 ± 31.72
|
0.5196
|
|
mHAQ
|
0.29 ± 0.38
|
0.38 ± 0.43
|
0.48 ± 0.53
|
<0.0001
|
|
CDAI
|
12.54 ± 10.18
|
14.61 ± 11.21
|
19.04 ± 14.91
|
<0.0001
|
|
Tender joints
|
3.53 ± 5.14
|
4.10 ± 5.46
|
5.68 ± 6.92
|
<0.0001*
|
|
Swollen joints
|
4.19 ± 5.41
|
4.76 ± 5.53
|
6.92 ± 6.73
|
<0.0001*
|
|
Patient global assessment
|
28.47 ± 23.70
|
34.31 ± 25.08
|
39.04 ± 27.26
|
<0.0001
|
|
MD global assessment
|
19.73 ± 15.59
|
23.22 ± 18.46
|
31.20 ± 23.03
|
<0.0001
|
|
Prednisone use
|
247 (24.41%)
|
138 (28.34%)
|
124 (38.27%)
|
<0.0001
|
|
Methotrexate use
|
696 (68.77%)
|
322 (66.12%)
|
191 (58.95%)
|
0.0050
|
- *Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; RA, rheumatoid arthritis; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.
